Up to 45% of the weight you lose on Ozempic or Wegovy isn't fat — it's the muscle your body spent decades building. For adults over 40, who are already fighting age-related muscle loss, this silent side effect is turning a weight loss win into a long-term metabolic disaster.
That's the headline from the STEP 1 clinical trial's DEXA substudy, which tracked body composition changes in semaglutide users over 68 weeks. And it's why physicians, researchers, and health experts are now urgently asking: what can GLP-1 users do to protect their muscle? The answer the research keeps pointing to is creatine — and the evidence in 2026 is stronger than ever.
The GLP-1 Muscle Loss Problem Is Bigger Than You Think
GLP-1 medications like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) work by suppressing appetite. That's also their core problem for muscle health: when you eat dramatically less food, your body doesn't just burn stored fat to make up the energy gap — it breaks down muscle tissue too.
The STEP 1 trial, the landmark study behind Wegovy's FDA approval, found that participants who lost an average of 15% of their body weight also lost 9.7% of their total lean body mass. A separate analysis of the same data, published in Cell Metabolism in 2025, found the proportion was even starker: roughly 45% of the weight lost in the trial came from lean tissue, not fat.
The tirzepatide trial (SURMOUNT-1) fared somewhat better, with lean mass accounting for approximately 25.7% of total weight lost — still significantly above the 25% threshold experts consider normal for weight loss interventions.
A 2026 UNC School of Medicine analysis sounded the alarm directly, advising physicians to carefully evaluate how GLP-1 patients' lean mass is being affected — because the downstream consequences of muscle loss go far beyond aesthetics.
Why Muscle Loss on GLP-1s Is Especially Dangerous After 40
Most adults over 40 are already in a race against sarcopenia — the age-related loss of muscle mass and strength. Starting around age 35, we lose approximately 1–2% of muscle mass per year if we're not actively counteracting it. After menopause, that rate accelerates due to declining estrogen and testosterone.
GLP-1 medications added on top of natural aging can create a compounding deficit. What the scale shows as "weight loss" may actually be a worsening of the body composition ratio — less fat, but also significantly less muscle. And muscle isn't just about how you look or feel in the gym. It's your body's metabolic engine.
Skeletal muscle is responsible for the majority of glucose disposal in your body. It drives your resting metabolic rate. It protects your joints, prevents falls, and is one of the strongest independent predictors of longevity in studies of adults over 60. When you lose it, you don't just get weaker — you get sicker, faster.
The 2026 Research That Changes the Equation
Here's the part most GLP-1 coverage is missing: muscle loss on these medications is not inevitable. The 2026 SEMALEAN trial, a prospective study published in Diabetes, Obesity and Metabolism, tracked 115 patients on semaglutide 2.4mg for 12 months using DEXA body composition scans and functional strength testing. Despite weight loss, the proportion of lean mass relative to total body mass increased over the treatment period. Sarcopenic obesity dropped from 49% at baseline to 33% at 12 months. Handgrip strength improved.
The key difference? These patients maintained adequate protein intake and physical activity throughout treatment. The muscle loss seen in the STEP 1 registration trial wasn't an inevitable drug effect — it was partly a consequence of how patients ate and moved.
Even more striking: a 2026 case series documented a patient who lost 33% of their total body weight over 115 weeks on GLP-1 therapy combined with resistance training and structured protein intake. Of that weight loss, 91.2% came from fat and only 8.7% from lean tissue — a radically different outcome than the registration trials, achieved through the same medication but with a comprehensive supporting protocol.
The Three-Part Protocol That Protects Your Muscle
Based on the clinical data, researchers and clinicians now broadly agree on three core strategies for protecting lean mass on GLP-1 medications:
- Protein priority: The 2025–2030 Dietary Guidelines updated recommendations to 1.2–1.6g of protein per kilogram of body weight daily for adults in active weight loss. The International Society of Sports Nutrition recommends up to 2.2g/kg for those doing regular resistance training. For most adults over 40, this translates to 100–150g of protein per day.
- Resistance training: At minimum two to three sessions per week focused on compound movements (squats, deadlifts, rows, presses). The mechanical stimulus of lifting tells your body muscle is in demand and worth keeping.
- Creatine supplementation: This is where the 2026 evidence has become particularly compelling.
Why Creatine Is Becoming the Standard Recommendation for GLP-1 Users Over 40
Creatine monohydrate is one of the most studied sports supplements in existence — over 200 peer-reviewed trials over three decades. But its role in the GLP-1 context is relatively new, and the 2025–2026 research is shining a spotlight on why it matters so much for adults over 40 specifically.
Here's the mechanism: when you're in a calorie deficit (which GLP-1 medications essentially enforce), your muscles experience increased metabolic stress. ATP — the energy currency your cells run on — gets depleted faster. Creatine phosphate in your muscle cells acts as a rapid-recharge buffer, allowing ATP to be regenerated during high-intensity effort. More available ATP means your muscles can work harder, recover faster, and signal more strongly for growth and maintenance.
A 2021 study published in Med Sci Sports Exerc confirmed that creatine supplementation actively encourages the body to hold onto muscle tissue during caloric restriction — working synergistically with resistance training to preserve lean mass even when calories are down.
A 2026 randomized controlled trial published in Frontiers in Nutrition found that 6g of creatine monohydrate daily was associated with significant improvements in both fatigue and strength in patients experiencing chronic energy depletion — conditions remarkably similar to what GLP-1 users face during dose escalation phases.
And creatine doesn't just help your muscles. For adults over 40 on GLP-1 medications, the cognitive support is equally important. A 2022 study found that creatine supplementation increased brain creatine concentrations by 15%, with corresponding improvements in cognitive performance. A 2025 analysis in Neurological Sciences found that low creatinine levels — a byproduct of creatine metabolism and age-related muscle loss — were associated with increased risk of Alzheimer's disease. Given that GLP-1 users often report mental fog during dose escalation, the brain-energy benefits of creatine are particularly relevant.
What the Research-Backed Dose Looks Like
The standard recommendation is 3–5 grams of creatine monohydrate daily, mixed into water or your protein shake. You don't need to load creatine (taking 20g/day for a week to saturate faster) — the Cleveland Clinic's 2024 analysis confirmed loading makes no meaningful long-term difference and may increase gastrointestinal side effects.
For GLP-1 users specifically: if you experience a sensitive stomach on injection days, take creatine on other days. Creatine is safe to combine with GLP-1 medications — there is no known pharmacological interaction between creatine and semaglutide or tirzepatide, as they operate through entirely different mechanisms.
One note on the scale: creatine causes 2–3 pounds of water retention in muscle tissue. This is normal, temporary, and actually a sign the creatine is working. It is not fat gain and has no negative health implications — your GLP-1 medication is still working.
What This Means For You: A Practical Action Plan
If you're over 40 and currently taking or considering a GLP-1 medication, here's the protocol that the 2026 evidence supports:
- Get a DEXA scan baseline. You cannot manage what you cannot measure. Before or soon after starting a GLP-1, get a body composition scan to know your starting lean mass. Repeat every 3–6 months while on medication.
- Hit your protein number every single day. Calculate 1.2g multiplied by your body weight in kilograms. That's your floor. Make protein the first thing on your plate at every meal. If appetite is suppressed, use protein shakes to close the gap.
- Lift weights at least twice a week. Full-body sessions focused on compound movements. Don't skip legs — the quadriceps, hamstrings, and glutes are your largest muscle groups and the most important for long-term metabolic health.
- Add 5g of creatine monohydrate daily. Mix into water. Take it consistently — creatine works through accumulation in muscle tissue over 2–4 weeks. It doesn't require perfect timing.
- Track function, not just the scale. Are you getting stronger? Is your grip strength improving? Can you do more reps than last month? These functional markers matter far more than the number on the scale.
🧪 ATO Health Creatine — Formulated for Adults Over 40
Micronized creatine monohydrate. No fillers, no creatine HCl gimmicks — just the form backed by 200+ studies. Especially important if you're on a GLP-1 medication and need to protect your lean mass.
Frequently Asked Questions
Q: How much muscle do you lose on Ozempic or Wegovy?
A: The STEP 1 trial found participants on semaglutide lost 9.7% of total lean body mass over 68 weeks, with up to 45% of all weight lost coming from lean tissue rather than fat. Tirzepatide (SURMOUNT-1 trial) showed a somewhat better ratio, with 25.7% of weight lost from lean mass. However, the 2026 SEMALEAN trial showed these losses are significantly reducible with resistance training and adequate protein intake.
Q: Can you take creatine while on Ozempic or Wegovy?
A: Yes. There is no known pharmacological interaction between creatine and semaglutide or tirzepatide — they work through completely different mechanisms. The standard recommendation is 3–5g of creatine monohydrate daily. If you experience stomach sensitivity on injection days, take creatine on other days. Always consult your doctor if you have kidney concerns or diabetes-related complications.
Q: Does creatine help with muscle loss on GLP-1 medications?
A: Yes, based on the available evidence. Creatine helps preserve lean mass during caloric restriction by supporting ATP regeneration and protein synthesis in muscle cells. A 2021 study confirmed creatine encourages muscle retention during calorie deficits. It works best as part of a complete protocol that includes adequate protein (1.2–1.6g/kg/day) and resistance training two to four times per week.
Q: Will creatine cause weight gain while on GLP-1 medications?
A: Creatine causes 2–3 pounds of water retention in muscle tissue during the first 1–2 weeks of use. This is normal, not fat gain, and doesn't indicate your GLP-1 medication stopped working. The scale number may rise slightly while your body composition (fat vs. muscle ratio) is simultaneously improving.
Q: How much protein should I eat on Ozempic over 40?
A: Research supports 1.2–1.6 grams of protein per kilogram of body weight per day for adults in active weight loss, with the International Society of Sports Nutrition recommending up to 2.2g/kg for those doing regular resistance training. For most adults over 40, this means 100–150g of protein daily. Prioritize protein at every meal — eat it first before vegetables or carbohydrates to ensure you hit your target even with reduced appetite.
Q: Is the muscle loss from GLP-1 medications permanent?
A: No, but recovery requires active effort. The 2026 SEMALEAN trial showed that with proper protein intake and physical activity, body composition can actually improve while on GLP-1 medications — with sarcopenic obesity prevalence dropping from 49% to 33%. A case series showed 91.2% of weight lost could come from fat rather than muscle when combining GLP-1 medications with resistance training and adequate protein. Creatine supplementation further supports lean mass preservation and recovery.
Sources & Further Reading
- Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021. STEP 1 Trial DEXA Substudy, PMC8089287.
- Cell Metabolism lean mass analysis of STEP 1 data. S1550-4131(25)00331-6, 2025.
- SURMOUNT-1 Trial body composition data. Diabetes, Obesity and Metabolism, dom.15728.
- SEMALEAN Study: Prospective trial of semaglutide 2.4mg body composition changes over 12 months. Diabetes, Obesity and Metabolism, 2026. PMID: 41068996.
- UNC School of Medicine GLP-1 lean mass advisory, 2026.
- Rockwell JA et al. "Creatine supplementation affects muscle creatine during energy restriction." Med Sci Sports Exerc, 2001. PMID: 11194113.
- Dos Santos MSC et al. "Creatine supplementation on fatigue." Frontiers in Nutrition, 2026. PMCID: PMC13058949.
- Forbes SC et al. "Effects of Creatine Supplementation on Brain Function and Health." Nutrients, 2022. PMCID: PMC8912287.
- Wang P et al. "Association of creatinine level with neurodegenerative disorders." Neurological Sciences, 2025. PMID: 40643880.
- International Society of Sports Nutrition Position Stand: Protein and Exercise, updated 2023.